The circulating endothelial cell in cancer: Towards marker and target identification

Inis Martin-Padura, F. Bertolini

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Circulating endothelial cell (CEC) and progenitor (CEP) number and viability are modulated in various pathological conditions including cancer. There is increasing evidence showing that CEC and CEP play a role in cancer progression and metastasis in different animal models. At the clinical level, emerging data support that CEC and CEP kinetics and viability might predict the efficacy on anticancer drug combinations that include antiangiogenic agents. On the basis of these observations, CEC and CEP measurements have attractive potential diagnostic and therapeutic applications for malignant diseases.

Original languageEnglish
Pages (from-to)3780-3789
Number of pages10
JournalCurrent Pharmaceutical Design
Volume14
Issue number36
DOIs
Publication statusPublished - 2008

Fingerprint

Endothelial Cells
Antineoplastic Combined Chemotherapy Protocols
Neoplasms
Angiogenesis Inhibitors
Cell Survival
Animal Models
Cell Count
Neoplasm Metastasis
Endothelial Progenitor Cells
Therapeutics

Keywords

  • Angiogenesis
  • Cancer
  • Endothelial cells
  • Endothelial progenitors
  • Tumor
  • Vasculogenesis

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

The circulating endothelial cell in cancer : Towards marker and target identification. / Martin-Padura, Inis; Bertolini, F.

In: Current Pharmaceutical Design, Vol. 14, No. 36, 2008, p. 3780-3789.

Research output: Contribution to journalArticle

@article{d30b03de47c740d88e2c77b14b7835dc,
title = "The circulating endothelial cell in cancer: Towards marker and target identification",
abstract = "Circulating endothelial cell (CEC) and progenitor (CEP) number and viability are modulated in various pathological conditions including cancer. There is increasing evidence showing that CEC and CEP play a role in cancer progression and metastasis in different animal models. At the clinical level, emerging data support that CEC and CEP kinetics and viability might predict the efficacy on anticancer drug combinations that include antiangiogenic agents. On the basis of these observations, CEC and CEP measurements have attractive potential diagnostic and therapeutic applications for malignant diseases.",
keywords = "Angiogenesis, Cancer, Endothelial cells, Endothelial progenitors, Tumor, Vasculogenesis",
author = "Inis Martin-Padura and F. Bertolini",
year = "2008",
doi = "10.2174/138161208786898635",
language = "English",
volume = "14",
pages = "3780--3789",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "36",

}

TY - JOUR

T1 - The circulating endothelial cell in cancer

T2 - Towards marker and target identification

AU - Martin-Padura, Inis

AU - Bertolini, F.

PY - 2008

Y1 - 2008

N2 - Circulating endothelial cell (CEC) and progenitor (CEP) number and viability are modulated in various pathological conditions including cancer. There is increasing evidence showing that CEC and CEP play a role in cancer progression and metastasis in different animal models. At the clinical level, emerging data support that CEC and CEP kinetics and viability might predict the efficacy on anticancer drug combinations that include antiangiogenic agents. On the basis of these observations, CEC and CEP measurements have attractive potential diagnostic and therapeutic applications for malignant diseases.

AB - Circulating endothelial cell (CEC) and progenitor (CEP) number and viability are modulated in various pathological conditions including cancer. There is increasing evidence showing that CEC and CEP play a role in cancer progression and metastasis in different animal models. At the clinical level, emerging data support that CEC and CEP kinetics and viability might predict the efficacy on anticancer drug combinations that include antiangiogenic agents. On the basis of these observations, CEC and CEP measurements have attractive potential diagnostic and therapeutic applications for malignant diseases.

KW - Angiogenesis

KW - Cancer

KW - Endothelial cells

KW - Endothelial progenitors

KW - Tumor

KW - Vasculogenesis

UR - http://www.scopus.com/inward/record.url?scp=61449147353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449147353&partnerID=8YFLogxK

U2 - 10.2174/138161208786898635

DO - 10.2174/138161208786898635

M3 - Article

C2 - 19128231

AN - SCOPUS:61449147353

VL - 14

SP - 3780

EP - 3789

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 36

ER -